Now I have all the information I need. Let me produce the final consolidated review.

---

## Summary

The paper tackles the cold-start problem in biomedical image classification by proposing a three-component framework: self-supervised pretraining (SimCLR) to build meaningful latent representations, furthest-point sampling (FPS) to select informative data points for annotation, and model soups to overcome the lack of a validation set. The approach is tested on four diverse biomedical datasets. The paper claims to outperform the state-of-the-art (Cold PAWS) with substantial speed advantages.

## Strengths

1. **Computational efficiency of FPS over Cold PAWS is clearly demonstrated.** Table 3 shows FPS runs 5–10× faster than Cold PAWS (e.g., 128s vs 1350s on Jurkat), with a concrete complexity analysis (O(nm) vs O(n²m)). This is a genuine practical advantage for large biomedical datasets.

2. **Model soups provides a principled solution to the no-validation-set problem inherent in cold-start settings.** Figure 6 shows consistent F1-macro gains from weight averaging across learning rates (e.g., Matek from ~0.42 to ~0.46). This directly addresses a limitation the paper correctly identifies in prior work.

3. **Systematic ablation across SSL methods and clustering hyperparameters.** The paper compares SimCLR, SwAV, and DINO (Figure 3, Figure 5), and tests FPS against k-means-based sampling across five different k values (Figure 4). This provides a thorough assessment of design choices.

4. **Evaluation on four diverse biomedical datasets** (microscopy, dermoscopy, fundus, flow cytometry) covering varying sizes (3.6k–32k) and class imbalances, supporting the claim of cross-domain applicability.

5. **Upper-bound comparison via fully supervised training on all labels** (Table 1) provides context for how well the cold-start selection narrows the gap to the fully supervised oracle.

## Weaknesses

### Major

- **The comparison against Cold PAWS (the claimed state-of-the-art) is compromised in two ways.** First, the paper strips Cold PAWS of its semi-supervised component, stating this is "to ensure a fair comparison between models designed to accommodate unlabeled data and those that do not" (Section 4.2). While the reasoning is disclosed, this means the paper does not compare against the *original method as proposed and validated in its own paper*. The abstract's claim of outperforming "the state-of-the-art" is therefore misleading — it compares against a modified variant, not the published method. Second, the paper asserts that "Cold PAWS utilizes the testing dataset for early stopping, potentially introducing information leakage" (Section 4.3) without citing any source or providing evidence. This is a serious methodological accusation about a competitor and should either be verified with evidence or removed. Together, these issues undermine the paper's headline comparative claim.

- **Statistical significance is not established, and the practical gains over random sampling are weak on multiple datasets.** The paper reports means and standard deviations from five runs but performs no statistical test. Examination of the reported values (Table 1) shows that on Retinopathy, FPS (0.28 ± 0.10) and random (0.21 ± 0.04) have substantially overlapping distributions. On Jurkat, the best method (closest/farthest, 0.47 ± 0.03) barely exceeds random (0.43 ± 0.04). Only on Matek is the gap clearly outside the noise. With five runs and no significance test, the claim of consistent outperformance over random is not supported by rigorous evidence across all datasets.

- **The "7% improvement" headline claim is ambiguous.** The abstract states "achieves a 7% improvement on leukemia blood cell classification task" without specifying whether this is absolute or relative F1-macro gain, or which baseline (random or Cold PAWS) it refers to. From the reported numbers (FPS 0.46 vs random 0.28), a literal reading yields an absolute difference of 18 percentage points or a relative improvement of 64% — neither is 7%. The paper should define this precisely.

### Minor

- **No comparison to k-center sampling.** FPS is closely related to the k-center objective for diversity-based sampling, which is a standard baseline in the active learning literature (e.g., Sener & Savarese, 2018). The paper should either compare or explicitly justify omission.

- **No baseline isolating the contribution of SSL pretraining.** The paper does not compare FPS in the SSL latent space to FPS applied directly to pixel-space features (or raw pixels). This would isolate how much of the improvement comes from the SSL representation vs the sampling algorithm itself.

- **Model soups is not compared to the simpler alternative of holding out a small portion of the annotation budget as a validation set.** The paper motivates model soups by the lack of validation data, but does not test whether using, e.g., 10–20 images from the budget for early stopping yields comparable or better results. If the simpler approach works as well, the claimed advantage of model soups is diminished.

- **The paper critiques clustering methods for the "curse of dimensionality" in 128D spaces (citing Aggarwal et al., 2001) but uses FPS in a 512-dimensional SimCLR latent space without addressing the same concern.** While FPS is less dependent on density estimation than clustering, the concentration of distances in high dimensions is a known issue that the paper should at least acknowledge or provide evidence that distances remain discriminative.

### Trivial

- The superscript footnote markers in the text (e.g., ".1)", ".4)", ".5)") appear to reference an appendix that was stripped — these should be properly formatted.
- Minor grammatical issues throughout (e.g., "the the time complexity" on line 123).

## Nice-to-Haves

- Including results at annotation budgets of 200 and 500 (which the paper mentions conducting but does not present in the main text) would strengthen claims about generality.
- Reporting confidence intervals or a simple permutation test for the primary comparisons would substantially increase confidence in the results.

## Removed Points

The following points from the reviewers are removed with justification:

1. **Criticism that the claim "none of the previous studies have applied their methods to the biomedical domain" is inaccurate.** The reviewer asserts Chandra et al. (2021) and Shetab Boushehri et al. (2022) work with biomedical data, but the paper's claim is specifically about cold-start *methods* being applied to biomedical domains. Without external verification of what data those papers used, this criticism cannot be confirmed. Removed per the "do not mention missing related works" rule.

2. **Criticism about results only shown for a single annotation budget.** The paper explicitly states "We conduct similar experiments on bigger annotation budget (200, and 500 images)" with a footnote marker presumably pointing to an appendix. The parser strips appendix content. Per the rules, weaknesses about missing appendix content are removed.

3. **Missing related works (e.g., "the paper does not test whether that negative result extends to biomedical datasets — it simply assumes it does").** This is a speculation about what the paper should have done, not a verifiable flaw in what it did do. Removed as speculative.

4. **Formatting nitpicks (typos, whitespace, garbled characters).** These are parser artifacts, not author errors. Removed.

5. **Strength about FPS outperforming Cold PAWS and random.** This strength conflicts with the verified weakness that the Cold PAWS comparison is modified. Per instructions, when a strength and weakness disagree, the weakness wins. Moved here.

6. **Strength about evaluation on four diverse biomedical datasets addressing a gap noted in prior work.** While the evaluation is genuinely diverse, the framing that "none of the previous studies have applied their methods to the biomedical domain" is a disputed claim. Moved here for caution. (The diversity of datasets remains a genuine positive, retained in Strengths above.)

7. **Generic strengths about the problem being important or the approach being "simple and well-motivated."** These lack specific evidence and are superficial. Removed.

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface insights that meaningfully extend what the paper itself articulates about the cold-start problem, FPS sampling, or model soups in biomedical settings.

## Suggestions

1. **Fix the Cold PAWS comparison.** Either (a) reimplement the original method exactly (including its semi-supervised component) using the same early-stopping protocol, and report that comparison alongside the modified version, or (b) clearly state that the comparison is against a variant of Cold PAWS that uses only labeled data, and adjust all claims (including the abstract) to reflect this. Retract or substantiate the test-set leakage claim.

2. **Add statistical significance testing.** For the primary comparisons (FPS vs random, FPS vs Cold PAWS), report a simple paired bootstrap or permutation test across the five runs.

3. **Clarify the "7% improvement" claim** by specifying the baseline, the metric, and whether it is absolute or relative.

4. **Add a k-center baseline** and a **no-SSL baseline** (FPS in pixel space) to better isolate the contributions of each component.

5. **Acknowledge and address the curse of dimensionality concern** for the 512D latent space, e.g., by analyzing the distribution of pairwise distances or comparing FPS performance before and after dimensionality reduction.

## Score and Decision

The paper addresses a genuine problem and proposes a sensible, computationally efficient framework. However, the experimental validation has two decisive weaknesses: the SOTA comparison is compromised by modifying the baseline without clear justification, and the reported improvements over random are not statistically supported across multiple datasets. These issues undermine the paper's central claims. The framework is promising and could become a solid contribution with revisions, but in its current form the evidence does not convincingly support the claimed advantages.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>